Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication

Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement.

Abbisko Cayman’s subsidiary Abbisko Therapeutics has reported that results from its global Phase 3 MANEUVER trial of pimicotinib in tenosynovial giant cell tumour have been published in The Lancet, underscoring the quality and robustness of its clinical research. The 94-patient, multicenter study showed significant efficacy and a generally favorable safety profile, supporting China’s 2025 approval, ongoing U.S. and other regulatory reviews, and Merck’s plans to commercialize the drug globally.

The publication in a leading international medical journal enhances Abbisko’s academic and clinical standing, potentially strengthening its competitive position in targeted oncology and rare disease treatments. For stakeholders, the data validation and existing China approval highlight near-term commercial prospects, though the company cautions that ultimate global commercialization outcomes remain uncertain and subject to regulatory decisions and market execution.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biopharmaceutical industry with a focus on innovative oncology and immunology therapies. The group develops small-molecule drugs such as pimicotinib, a highly selective CSF-1R inhibitor targeting tenosynovial giant cell tumour, and partners with global pharma major Merck for worldwide commercialization.

Average Trading Volume: 1,568,817

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.08B

For detailed information about 2256 stock, go to TipRanks’ Stock Analysis page.